CYTK vs. JAZZ, ELAN, VKTX, ITCI, IONS, CERE, APLS, BPMC, ASND, and LEGN
Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Ionis Pharmaceuticals (IONS), Cerevel Therapeutics (CERE), Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical preparations" industry.
Cytokinetics (NASDAQ:CYTK) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Jazz Pharmaceuticals received 323 more outperform votes than Cytokinetics when rated by MarketBeat users. Likewise, 80.49% of users gave Jazz Pharmaceuticals an outperform vote while only 79.14% of users gave Cytokinetics an outperform vote.
Cytokinetics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.
89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 3.4% of Cytokinetics shares are held by insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Jazz Pharmaceuticals has a net margin of 10.82% compared to Cytokinetics' net margin of -6,988.63%. Jazz Pharmaceuticals' return on equity of 31.27% beat Cytokinetics' return on equity.
Jazz Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cytokinetics currently has a consensus price target of $79.33, indicating a potential upside of 21.42%. Jazz Pharmaceuticals has a consensus price target of $195.08, indicating a potential upside of 78.22%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Cytokinetics.
In the previous week, Cytokinetics had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 10 mentions for Cytokinetics and 8 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.70 beat Cytokinetics' score of 0.44 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.
Summary
Jazz Pharmaceuticals beats Cytokinetics on 13 of the 18 factors compared between the two stocks.
Get Cytokinetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytokinetics Competitors List
Related Companies and Tools
